ISLR and nonpapillary renal cell carcinoma: However, the analysis of patients with ccRCC and UC treated with ICB therapy showed that the Meflin-high groups showed a better objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) than the Meflin-low groups (Fig. 1c, d and Table 1).